Literature DB >> 3096887

Interaction of complement with serum-sensitive and serum-resistant strains of Pseudomonas aeruginosa.

N L Schiller, K A Joiner.   

Abstract

The interaction of complement with the following two strains of Pseudomonas aeruginosa was examined: 144M, a mucoid, serum-sensitive strain bearing short lipopolysaccharide O chains, and 144M-SR, a mucoid, serum-resistant strain bearing long lipopolysaccharide O chains isolated by repeated passage of 144M in increasing concentrations of pooled normal human serum (PNHS). While significant killing of 144M occurred in 5 to 40% PNHS, no killing of 144M-SR was observed. Both strains activated complement, especially 144M-SR which consumed 88.7, 96.4, and 100% of the available complement 3 (C3), C5, and C9, respectively, in 10% PNHS during a 60-min incubation at 37 degrees C. Although it activated more C3 than did 144M (54.9% consumption), 144M-SR bound only half as much C3 as 144M. Similarly, although 144M-SR activated more C9 than did 144M (50.0% consumption in 60 min), there was considerably less C9 attached to 144M-SR (2,990 molecules of C9 per bacterium) than to 144M (13,700 molecules per bacterium) after 60 min of incubation. Furthermore, only 162 molecules of the C9 bound to 144M-SR remained bound after treatment with 0.1% trypsin, while 5,692 molecules of the C9 bound to 144M remained bound under similar conditions. These results show that the serum resistance of 144M-SR does not represent a failure to activate complement efficiently, but instead reflects failure of the assembled terminal complement complex C5b-9 to insert stably into the outer membrane of this strain.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3096887      PMCID: PMC260224          DOI: 10.1128/iai.54.3.689-694.1986

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  31 in total

1.  The sensitivity of smooth and rough gram-negative bacteria to the immune bactericidal reaction.

Authors:  L H Muschel; L J Larsen
Journal:  Proc Soc Exp Biol Med       Date:  1970-01

2.  [Studies on the immune bacteriolysis. XIV. Requirement of all nine components of complement for immune bacteriolysis].

Authors:  K Inoue; K Yonemasu; A Takamizawa; T Amano
Journal:  Biken J       Date:  1968-09

3.  The serum bactericidal reaction. 3. Antibody and complement requirements for killing a rough Escherichia coli.

Authors:  J N Goldman; S Ruddy; K F Austen; D S Feingold
Journal:  J Immunol       Date:  1969-06       Impact factor: 5.422

Review 4.  Studies on the mechanism of bacterial resistance to complement-mediated killing and on the mechanism of action of bactericidal antibody.

Authors:  K A Joiner
Journal:  Curr Top Microbiol Immunol       Date:  1985       Impact factor: 4.291

5.  Release of lipopolysaccharide by EDTA treatment of E. coli.

Authors:  L Leive
Journal:  Biochem Biophys Res Commun       Date:  1965-11-22       Impact factor: 3.575

6.  Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors.

Authors:  L S Young; D Armstrong
Journal:  J Infect Dis       Date:  1972-09       Impact factor: 5.226

7.  Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases.

Authors:  N Holby; S Olling
Journal:  Acta Pathol Microbiol Scand C       Date:  1977-04

8.  Sensitivity of Pseudomonas aeruginosa to normal serum and to polymyxin.

Authors:  L H Muschel; L A Ahl; M W Fisher
Journal:  J Bacteriol       Date:  1969-05       Impact factor: 3.490

9.  Sensitivity of rough gram-negative bacteria to the bactericidal action of serum.

Authors:  D Rowley
Journal:  J Bacteriol       Date:  1968-05       Impact factor: 3.490

10.  Elastase of Pseudomonas aeruginosa: inactivation of complement components and complement-derived chemotactic and phagocytic factors.

Authors:  D R Schultz; K D Miller
Journal:  Infect Immun       Date:  1974-07       Impact factor: 3.441

View more
  20 in total

Review 1.  Target recognition failure by the nonspecific defense system: surface constituents of pathogens interfere with the alternative pathway of complement activation.

Authors:  R D Horstmann
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

2.  Determinants for persistence of Pseudomonas aeruginosa in hospitals: interplay between resistance, virulence and biofilm formation.

Authors:  S J Kaiser; N T Mutters; A DeRosa; C Ewers; U Frank; F Günther
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-12       Impact factor: 3.267

3.  Pseudomonas aeruginosa alginate in cystic fibrosis sputum and the inflammatory response.

Authors:  S S Pedersen; A Kharazmi; F Espersen; N Høiby
Journal:  Infect Immun       Date:  1990-10       Impact factor: 3.441

4.  Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity.

Authors:  E M Peterson; G M Zhong; E Carlson; L M de la Maza
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

5.  Determination of serum bactericidal activity against Escherichia coli by an automated photometric method.

Authors:  F Crokaert; M J Lismont; M P van der Linden; E Yourassowsky
Journal:  J Clin Microbiol       Date:  1988-10       Impact factor: 5.948

6.  Murine complement interactions with Pseudomonas aeruginosa and their consequences during pneumonia.

Authors:  John G Younger; Sunita Shankar-Sinha; Marc Mickiewicz; Adam S Brinkman; Gabriel A Valencia; J Vidya Sarma; Ellen M Younkin; Theodore J Standiford; Firas S Zetoune; Peter A Ward
Journal:  Am J Respir Cell Mol Biol       Date:  2003-10       Impact factor: 6.914

7.  Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway.

Authors:  S K Kochi; R C Johnson
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

8.  Effects of the combination of lipopolysaccharide-specific monoclonal antibodies and sparfloxacin against Pseudomonas aeruginosa pneumonia in neutropenic mice.

Authors:  K Oishi; F Sonoda; A Iwagaki; S Kobayashi; T Nagatake; K Matsumoto
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

9.  A protective human monoclonal antibody directed to the outer core region of Pseudomonas aeruginosa lipopolysaccharide.

Authors:  M Terashima; I Uezumi; T Tomio; M Kato; K Irie; T Okuda; S Yokota; H Noguchi
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

10.  Pseudomonas aeruginosa variants isolated from patients with cystic fibrosis are killed by a bactericidal protein from human polymorphonuclear leukocytes.

Authors:  C M Siefferman; W E Regelmann; B H Gray
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.